MITF and melanoma: The role of MITF in melanoma progression and resistance to targeted therapy appears paradoxical; some studies have found that CMs expressing MITF are well differentiated and have a favourable prognosis 19 and those with low MITF expression have an invasive phenotype and are intrinsically resistant to MAPK inhibition 20, whereas others have found that activation of a robust MITF transcriptional program triggers differentiation into highly pigment‐producing drug resistant cells 21.